H.C. Wainwright Downplays Roche Trial Failure Impact on Olema's OPERA-02

H.C. Wainwright analysts state that Roche’s recent setback in a Phase 3 trial for its multiple sclerosis drug does not directly affect Olema Therapeutics’ OPERA-02 trial results, citing distinct trial designs and patient populations. The assessment comes amid market scrutiny of late-stage neurology drug developments.

• Roche’s Phase 3 trial failed to meet its primary endpoint with a 12.4% relapse rate reduction.
• Olema’s OPERA-02 trial includes 382 patients and targets disability progression at 12 months.
• H.C. Wainwright identifies no mechanistic or clinical overlap between Roche’s drug and Olema’s compound.
• Olema’s stock (OLEM) dipped 1.8% post-Roche announcement, signaling limited market impact.
• Top-line results for OPERA-02 are expected in Q3 2026.
• H.C. Wainwright maintains a 'Hold' rating on OLEM, citing distinct trial design and patient populations.